Warning on GLP-1 Receptor Agonists Use Among Australian Women

A recent study published in the Medical Journal of Australia serves as a warning regarding the use of drugs known as “GLP-1 receptor agonists” among Australian women of childbearing age. These drugs, including Ozempic, are increasingly used for weight loss, yet many women using them do not adhere to effective contraceptive methods despite the known risks during pregnancy.

Increased Use of GLP-1 Among Non-Diabetic Women

The original purpose of developing these drugs was to manage type 2 diabetes, but they have gained popularity for their ability to suppress appetite and aid in weight loss. However, the study reveals that most prescriptions are given to non-diabetic women, indicating a shift in the use of these drugs.

In 2022 alone, more than 6,000 women began using these medications, with 90% of them not having diabetes. This widespread use among women of reproductive age raises questions about awareness of potential risks during pregnancy.

Potential Risks to Pregnancy and Fetus

The study’s findings indicate that 2.2% of women became pregnant within six months of starting GLP-1 treatment, with higher pregnancy rates among younger women with diabetes and those without diabetes in their early thirties. The data also suggests that women with polycystic ovary syndrome were more likely to become pregnant, implying that weight loss might improve fertility, even if unintentionally.

Additionally, previous animal studies show that exposure to GLP-1 during pregnancy is linked to impaired fetal growth and structural abnormalities, which is concerning given the scarcity of available human data.

Importance of Improving Clinical Practice and Health Awareness

The study’s lead author, Associate Professor Luke Grzeskowiak, emphasizes the need to improve clinical practices in Australia to ensure reproductive health is part of every medical conversation when prescribing these drugs to any woman of childbearing age. He also stresses the necessity for clearer recommendations and guidelines for doctors regarding prescribing these drugs to women.

It is crucial for women to discuss the risks and benefits of GLP-1 medications with their doctors before use and to follow healthcare professionals’ prescriptions.

Conclusion

The recent study highlights the importance of raising awareness about the risks associated with the use of GLP-1 drugs among women of childbearing age. Despite the potential benefits for weight loss, the risks related to pregnancy require special attention. There should be clearer guidance from doctors and awareness among women about the importance of using effective contraception when taking these drugs. Ultimately, more studies are necessary to assess the impact of these drugs on pregnancy and fetuses to ensure their safe and effective use.